

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

<b>CLINICAL BENEFIT</b>	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
<b>Effective Date:</b>	<b>4/1/2026</b>

## I. POLICY

Nonpulsed radiofrequency denervation of cervical (C3 to 4 and below), thoracic, lumbar, and lumbosacral facet joints is considered **medically necessary** when ALL of the following criteria are met.

- No prior spinal fusion surgery in the vertebral level being treated; **AND**
- Disabling back (thoracic or lumbosacral) or neck (cervical) pain, suggestive of facet joint origin as evidenced by absence of nerve root compression as documented in the medical record on history, physical, and radiographic evaluations; and the pain is not radicular; **AND**
- Pain has failed to respond to 3 months of conservative management, which may consist of therapies such as nonsteroidal anti-inflammatory medications, acetaminophen, manipulation, physical therapy, and a home exercise program; **AND**
- There has been a successful trial of controlled medial branch blocks (see Policy Guidelines section); **AND**
- If there has been a prior successful radiofrequency denervation, a minimum time of 6 months has elapsed since prior radiofrequency treatment (per side, per anatomic level of the spine).

Radiofrequency denervation is considered **investigational** for the treatment of chronic spinal or back pain for all uses that do not meet the criteria listed above. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits with this procedure.

All other methods of denervation are considered **investigational** for the treatment of chronic spinal or back pain, including, but not limited to, pulsed radiofrequency denervation, laser denervation, chemodenervation (e.g., alcohol, phenol, or high concentration local anesthetics), and cryodenervation. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits with this procedure.

If there has been a prior successful radiofrequency denervation, additional diagnostic medial branch blocks for the same level of the spine are **investigational**. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits with this procedure.

### Policy Guidelines

A successful trial of controlled diagnostic medial branch blocks consists of 2 separate positive blocks on different days with local anesthetic only (no steroids or other drugs), or a placebo-controlled series of blocks, under fluoroscopic guidance, that has resulted in at least a 50%

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

reduction in pain for the duration of the local anesthetic used (e.g., 3 hours longer with bupivacaine than lidocaine). No therapeutic intra-articular injections (i.e., steroids, saline, or other substances) should be administered for a period of at least 4 weeks prior to the diagnostic medial branch block. The diagnostic blocks should involve the levels being considered for radiofrequency treatment and should not be conducted under intravenous sedation unless specifically indicated (e.g., the individual is unable to cooperate with the procedure). These diagnostic blocks should be targeted to the likely pain generator. Single-level blocks lead to more precise diagnostic information, but multiple single-level blocks require several visits and additional exposure to radiation.

***Cross-References:***

**MP 5.048 Diagnosis and Treatment of Sacroiliac Joint Pain**

**MP 4.014 Epidural Steroid Injections for Back Pain and Facet Nerve Blocks**

**PRODUCT VARIATIONS**

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

**FEP PPO:** Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

**DESCRIPTION/BACKGROUND**

Facet denervation is used to treat neck and back pain originating in facet joints with degenerative changes. Diagnosis of facet joint pain is confirmed by response to nerve blocks. The goal of facet denervation is long-term pain relief. However, the nerves regenerate and, therefore, repeat procedures may be required.

**Facet Joint Denervation**

Percutaneous radiofrequency (RF) facet denervation is used to treat neck or back pain originating in facet joints with degenerative changes. Diagnosis of facet joint pain is confirmed by response to nerve blocks. Patients generally are sedated for the RF procedure. The goal of facet denervation is long-term pain relief. However, the nerves regenerate and, therefore, repeat procedures may be required.

Facet joint denervation is performed under local anesthetic and with fluoroscopic guidance. A needle or probe is directed to the median branch of the dorsal ganglion innervating the facet joint, where multiple thermal lesions are produced, typically by a RF generator. A variety of terms may be used to describe RF denervation (e.g., rhizotomy, rhizolysis). In addition, the structures to which the RF energy is directed may be referred to as facet joint, facet nerves, medial nerve or branch, median nerve or branch, or dorsal root ganglion.

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

Alternative methods of denervation include pulsed RF, laser, chemodenervation, and cryoablation. Pulsed RF consists of short bursts of electrical current of high voltage in the RF range but without heating the tissue enough to cause coagulation. RF is suggested as a possibly safer alternative to thermal RF facet denervation. Temperatures do not exceed 42°C at the probe tip versus temperatures in the 60° C range reached in thermal RF denervation, and tissues may cool between pulses. It is postulated that transmission across small unmyelinated nerve fibers is disrupted but not permanently damaged, while large, myelinated fibers are not affected. With chemical denervation, injections with a diluted phenol solution, a chemical ablating agent, are injected into the facet joint nerve.

**Regulatory Status**

A number of RF generators and probes have been cleared for marketing through the U.S. Food and Drug Administration’s (FDA) 510(k) process. In 2005, the SInergy® (Kimberly Clark/Baylis), a water-cooled single-use probe, was cleared by the FDA, listing the Baylis Pain Management Probe as a predicate device. The intended use is with an RF generator to create RF lesions in nervous tissue.

FDA product code: GXD.

**RATIONALE**

**SUMMARY OF EVIDENCE**

For individuals who have suspected facet joint pain who receive diagnostic medial branch blocks, the evidence includes systematic reviews, a small, randomized trial, and observational studies. Relevant outcomes are other test performance measures, symptoms, and functional outcomes. There is considerable controversy about the role of these blocks, the number of positive blocks required, and the extent of pain relief obtained. Studies have reported the use of single or double blocks and at least 50% or 80% improvement in pain and function. This evidence has suggested that there are relatively few patients who exhibit pain relief following 2 nerve blocks, but that these select patients may have pain relief for several months following RF denervation. Other large series have reported the prevalence and false-positive rates following controlled diagnostic blocks, although there are issues with the reference standards used in these studies because there is no criterion standard for the diagnosis of facet joint pain. There is level I evidence for the use of medial branch blocks for diagnosing chronic lumbar facet joint pain and level II evidence for diagnosing cervical and thoracic facet joint pain. The evidence available supports a threshold of at least 75% to 80% pain relief to reduce the false-positive rate. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have facet joint pain who receive RFA, the evidence includes systematic reviews and randomized controlled trials. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. While the evidence is limited to RCTs with small sample sizes, RF facet denervation appears to provide at least 50% pain relief in carefully selected patients. Diagnosis of facet joint pain is difficult. However, response to controlled medial branch blocks and the presence of tenderness over the facet joint appear to be reliable predictors of success. When RF facet denervation is successful, repeat treatments appear to

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

have similar success rates and duration of pain relief. Thus, the data indicate that, in carefully selected individuals facet joint pain, RF treatments can improve outcomes. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

**DEFINITIONS**

**FACET JOINT** refers to one of the zygapophyseal joints of the vertebral column between the articulating facets of each pair of vertebrae.

**NERVE BLOCK** refers to interruption of the conduction of impulses to peripheral nerves or nerve trunks by the injection of a local anesthetic solution.

**DISCLAIMER**

*Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.*

**CODING INFORMATION**

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

**Investigational; therefore, not covered:**

Procedure Codes							
64490	64491	64492	64493	64494	64495		

**Covered when medically necessary:**

Procedure Codes							
64633	64634	64635	64636				

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

<b>ICD-10-CM Diagnosis Codes</b>	<b>Description</b>
M47.011	Spondylosis; Anterior spinal artery compression syndromes, occipito-atlanto-axial region
M47.012	Spondylosis; Anterior spinal artery compression syndromes, cervical region
M47.013	Spondylosis; Anterior spinal artery compression syndromes, cervicothoracic region
M47.014	Spondylosis; Anterior spinal artery compression syndromes, thoracic region
M47.015	Spondylosis; Anterior spinal artery compression syndromes, thoracolumbar region
M47.016	Spondylosis; Anterior spinal artery compression syndromes, lumbar region
M47.021	Spondylosis; Vertebral artery compression syndromes, occipito-atlanto-axial region
M47.022	Spondylosis; Vertebral artery compression syndromes, cervical region
M47.11	Spondylosis; Other spondylosis with myelopathy, occipito-atlanto-axial region
M47.12	Spondylosis; Other spondylosis with myelopathy, cervical region
M47.13	Spondylosis; Other spondylosis with myelopathy, cervicothoracic region
M47.14	Spondylosis; Other spondylosis with myelopathy, thoracic region
M47.15	Spondylosis; Other spondylosis with myelopathy, thoracolumbar region
M47.16	Spondylosis; Other spondylosis with myelopathy, lumbar region
M47.21	Spondylosis; Other spondylosis with radiculopathy, occipito-atlanto-axial region
M47.22	Spondylosis; Other spondylosis with radiculopathy, cervical region
M47.23	Spondylosis; Other spondylosis with radiculopathy, cervicothoracic region
M47.24	Spondylosis; Other spondylosis with radiculopathy, thoracic region
M47.25	Spondylosis; Other spondylosis with radiculopathy, thoracolumbar region
M47.26	Spondylosis; Other spondylosis with radiculopathy, lumbar region
M47.27	Spondylosis; Other spondylosis with radiculopathy, lumbosacral region
M47.28	Spondylosis; Other spondylosis with radiculopathy, sacral and sacrococcygeal region
M47.811	Spondylosis; Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region
M47.812	Spondylosis; Spondylosis without myelopathy or radiculopathy, cervical region
M47.813	Spondylosis; Spondylosis without myelopathy or radiculopathy, cervicothoracic region
M47.814	Spondylosis; Spondylosis without myelopathy or radiculopathy, thoracic region
M47.815	Spondylosis; Spondylosis without myelopathy or radiculopathy, thoracolumbar region
M47.816	Spondylosis; Spondylosis without myelopathy or radiculopathy, lumbar region
M47.817	Spondylosis; Spondylosis without myelopathy or radiculopathy, lumbosacral region
M47.818	Spondylosis; Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

<b>ICD-10-CM Diagnosis Codes</b>	<b>Description</b>
M47.891	Spondylosis; Other spondylosis, occipito-atlanto-axial region
M47.892	Spondylosis; Other spondylosis, cervical region
M47.893	Spondylosis; Other spondylosis, cervicothoracic region
M47.894	Spondylosis; Other spondylosis, thoracic region
M47.895	Spondylosis; Other spondylosis, thoracolumbar region
M47.896	Spondylosis; Other spondylosis, lumbar region
M47.897	Spondylosis; Other spondylosis, lumbosacral region
M47.898	Spondylosis; Other spondylosis, sacral and sacrococcygeal region
M54.01	Dorsalgia; Panniculitis affecting regions of neck and back, occipito-atlanto-axial region
M54.02	Dorsalgia; Panniculitis affecting regions of neck and back, cervical region
M54.03	Dorsalgia; Panniculitis affecting regions of neck and back, cervicothoracic region
M54.04	Dorsalgia; Panniculitis affecting regions of neck and back, thoracic region
M54.05	Dorsalgia; Panniculitis affecting regions of neck and back, thoracolumbar region
M54.06	Dorsalgia; Panniculitis affecting regions of neck and back, lumbar region
M54.07	Dorsalgia; Panniculitis affecting regions of neck and back, lumbosacral region
M54.08	Dorsalgia; Panniculitis affecting regions of neck and back, sacral and sacrococcygeal region
M54.09	Dorsalgia; Panniculitis affecting regions, neck, and back, multiple sites in spine
M54.11	Dorsalgia; Radiculopathy, occipito-atlanto-axial region
M54.12	Dorsalgia; Radiculopathy, cervical region
M54.13	Dorsalgia; Radiculopathy, cervicothoracic region
M54.14	Dorsalgia; Radiculopathy, thoracic region
M54.15	Dorsalgia; Radiculopathy, thoracolumbar region
M54.16	Dorsalgia; Radiculopathy, lumbar region
M54.17	Dorsalgia; Radiculopathy, lumbosacral region
M54.18	Dorsalgia; Radiculopathy, sacral and sacrococcygeal region
M54.2	Dorsalgia; Cervicalgia
M54.31	Dorsalgia; Sciatica, right side
M54.32	Dorsalgia; Sciatica, left side
M54.41	Dorsalgia; Lumbago with sciatica, right side
M54.42	Dorsalgia; Lumbago with sciatica, left side
M54.5	Dorsalgia; Low back pain
M54.50	Low back pain, unspecified
M54.51	Vertebrogenic low back pain
M54.59	Other low back pain
M54.6	Dorsalgia; Pain in thoracic spine
M54.81	Dorsalgia; Occipital neuralgia
M54.89	Dorsalgia; Other dorsalgia

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

<b>ICD-10-CM Diagnosis Codes</b>	<b>Description</b>
M96.1	Post-laminectomy syndrome, not elsewhere classified

### REFERENCES

1. Boswell MV, Manchikanti L, Kaye AD, et al. A best-evidence systematic appraisal of the diagnostic accuracy and utility of facet (zygapophysial) joint injections in chronic spinal pain. *Pain Physician*. Jul-Aug 2015; 18(4): E497-533. PMID 26218947
2. Falco FJ, Datta S, Manchikanti L, et al. An updated review of the diagnostic utility of cervical facet joint injections. *Pain Physician*. Nov-Dec 2012; 15(6): E807-838. PMID 23159977
3. Falco FJ, Manchikanti L, Datta S, et al. Systematic review of the therapeutic effectiveness of cervical facet joint interventions: an update. *Pain Physician*. Nov-Dec 2012; 15(6): E839-868. PMID 23159978
4. Falco FJ, Manchikanti L, Datta S, et al. An update of the systematic assessment of the diagnostic accuracy of lumbar facet joint nerve blocks. *Pain Physician*. Nov-Dec 2012; 15(6): E869-907. PMID 23159979
5. Falco FJ, Manchikanti L, Datta S, et al. An update of the effectiveness of therapeutic lumbar facet joint interventions. *Pain Physician*. Nov-Dec 2012; 15(6): E909-953. PMID 23159980
6. Cohen SP, Strassels SA, Kurihara C, et al. Randomized study assessing the accuracy of cervical facet joint nerve (medial branch) blocks using different injectate volumes. *Anesthesiology*. Jan 2010; 112(1):144-152. PMID 19996954
7. Cohen SP, Stojanovic MP, Crooks M, et al. Lumbar zygapophysial (facet) joint radiofrequency denervation success as a function of pain relief during diagnostic medial branch blocks: a multicenter analysis. *Spine J*. May-Jun 2008; 8(3):498-504. PMID 17662665
8. Pampati S, Cash KA, Manchikanti L. Accuracy of diagnostic lumbar facet joint nerve blocks: a 2-year follow-up of 152 patients diagnosed with controlled diagnostic blocks. *Pain Physician*. Sep-Oct 2009; 12(5): 855-66. PMID 19787011
9. Manchikanti L, Pampati S, Cash KA. Making sense of the accuracy of diagnostic lumbar facet joint nerve blocks: an assessment of the implications of 50% relief, 80% relief, single block, or controlled diagnostic blocks. *Pain Physician*. Mar-Apr 2010; 13(2):133-143. PMID 20309379
10. Li H, An J, Zhang J, et al. Comparative efficacy of radiofrequency denervation in chronic low back pain: A systematic review and network meta-analysis. *Front Surg*. 2022; 9: 899538. PMID 35990102
11. Janapala RN, Manchikanti L, Sanapati MR, et al. Efficacy of Radiofrequency Neurotomy in Chronic Low Back Pain: A Systematic Review and Meta-Analysis. *J Pain Res*. 2021; 14: 2859-2891. PMID 34531682
12. Nath S, Nath CA, Pettersson K. Percutaneous lumbar zygapophysial (facet) joint neurotomy using radiofrequency current, in the management of chronic low back pain: a randomized double-blind trial. *Spine (Phila Pa 1976)*. May 20 2008; 33(12):1291-1297; discussion 1298. PMID 18496338

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

13. Tekin I, Mirzai H, Ok G, et al. A comparison of conventional and pulsed radiofrequency denervation in the treatment of chronic facet joint pain. *Clin J Pain*. Jul-Aug 2007; 23(6):524-529. PMID 17575493
14. van Wijk RM, Geurts JW, Wynne HJ, et al. Radiofrequency denervation of lumbar facet joints in the treatment of chronic low back pain: a randomized, double-blind, sham lesion-controlled trial. *Clin J Pain*. Jul-Aug 2005; 21(4):335-344. PMID 15951652
15. Lakemeier S, Lind M, Schultz W, et al. A comparison of intraarticular lumbar facet joint steroid injections and lumbar facet joint radiofrequency denervation in the treatment of low back pain: a randomized, controlled, double-blind trial. *Anesth Analg*. Jul 2013; 117(1):228-235. PMID 23632051
16. Manchikanti L, Kaye AD, Boswell MV, et al. A systematic review and best evidence synthesis of the effectiveness of therapeutic facet joint interventions in managing chronic spinal pain. *Pain Physician*. Jul-Aug 2015; 18(4): E535-582. PMID 26218948
17. Civelek E, Cansever T, Kabatas S, et al. Comparison of effectiveness of facet joint injection and radiofrequency denervation in chronic low back pain. *Turk Neurosurg*. Mar 2012; 22(2):200-206. PMID 22437295
18. Lord SM, Barnsley L, Wallis BJ, et al. Percutaneous radio-frequency neurotomy for chronic cervical zygapophyseal-joint pain. *N Engl J Med*. Dec 5, 1996; 335(23):1721-1726. PMID 8929263
19. van Eerd M, de Meij N, Kessels A, et al. Efficacy and Long-term Effect of Radiofrequency Denervation in Patients with Clinically Diagnosed Cervical Facet Joint Pain: A Double-blind Randomized Controlled Trial. *Spine (Phila Pa 1976)*. Mar 01 2021; 46(5): 285-293. PMID 33534439
20. Husted DS, Orton D, Schofferman J, et al. Effectiveness of repeated radiofrequency neurotomy for cervical facet joint pain. *J Spinal Disord Tech*. Aug 2008; 21(6):406-408. PMID 18679094
21. Schofferman J, Kine G. Effectiveness of repeated radiofrequency neurotomy for lumbar facet pain. *Spine (Phila Pa 1976)*. Nov 1 2004; 29(21):2471-2473. PMID 15507813
22. Smuck M, Crisostomo RA, Trivedi K, et al. Success of initial and repeated medial branch neurotomy for zygapophysial joint pain: a systematic review. *PM R*. Sep 2012; 4(9):686-692. PMID 22980421
23. Rambaransingh B, Stanford G, Burnham R. The effect of repeated zygapophysial joint radiofrequency neurotomy on pain, disability, and improvement duration. *Pain Med*. Sep 2010; 11(9):1343-1347. PMID 20667024
24. Manchikanti L, Singh V, Falco FJ, et al. Comparative outcomes of a 2-year follow-up of cervical medial branch blocks in management of chronic neck pain: a randomized, double-blind controlled trial. *Pain Physician*. Sep-Oct 2010; 13(5):437-450. PMID 20859313
25. Manchikanti L, Singh V, Falco FJ, et al. Evaluation of lumbar facet joint nerve blocks in managing chronic low back pain: a randomized, double-blind, controlled trial with a 2-year follow-up. *Int J Med Sci*. May, 28 2010; 7(3):124-135. PMID 20567613
26. Manchikanti L, Singh V, Falco FJ, et al. Comparative effectiveness of a one-year follow-up of thoracic medial branch blocks in management of chronic thoracic pain: a randomized, double-blind active controlled trial. *Pain Physician*. Nov-Dec 2010; 13(6):535-548. PMID 21102966
27. Manchikanti L, Singh V, Falco FJ, et al. The role of thoracic medial branch blocks in managing chronic mid and upper back pain: a randomized, double-blind, active-control trial with a 2-year followup. *Anesthesiol Res Pract*. 2012; 2012:585806. PMID 22851967

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

28. Moussa WM, Khedr W, Elsayy M. Percutaneous pulsed radiofrequency treatment of dorsal root ganglion for treatment of lumbar facet syndrome. *Clin Neurol Neurosurg.* Dec 2020; 199: 106253. PMID 33045627
29. Hashemi M, Hashemian M, Mohajerani SA, et al. Effect of pulsed radiofrequency in treatment of facet-joint origin back pain in patients with degenerative spondylolisthesis. *Eur Spine J.* Sep 2014; 23(9):1927-1932. PMID 24997616
30. Kroll HR, Kim D, Danic MJ, et al. A randomized, double-blind, prospective study comparing the efficacy of continuous versus pulsed radiofrequency in the treatment of lumbar facet syndrome. *J Clin Anesth.* Nov 2008; 20(7): 534-7. PMID 19041042
31. Van Zundert J, Patijn J, Kessels A, et al. Pulsed radiofrequency adjacent to the cervical dorsal root ganglion in chronic cervical radicular pain: a double blind sham controlled randomized clinical trial. *Pain.* Jan 2007; 127(1-2):173-182. PMID 17055165
32. Iwatsuki K, Yoshimine T, Awazu K. Alternative denervation using laser irradiation in lumbar facet syndrome. *Lasers Surg Med.* Mar 2007; 39(3):225-229. PMID 17345622
33. Joo YC, Park JY, Kim KH. Comparison of alcohol ablation with repeated thermal radiofrequency ablation in medial branch neurotomy for the treatment of recurrent thoracolumbar facet joint pain. *J Anesth.* Jun 2013; 27(3):390-395. PMID 23192698
34. Haufe SM, Mork AR. Endoscopic facet debridement for the treatment of facet arthritic pain-- a novel new technique. *Int J Med Sci.* May 25, 2010; 7(3):120-123. PMID 20567612
35. Watters WC, 3rd, Resnick DK, Eck JC, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: injection therapies, low-back pain, and lumbar fusion. *J Neurosurg Spine.* Jul 2014; 21(1):79-90. PMID 24980590
36. Manchikanti L, Kaye AD, Soin A, et al. Comprehensive Evidence-Based Guidelines for Facet Joint Interventions in the Management of Chronic Spinal Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines Facet Joint Interventions 2020 Guidelines. *Pain Physician.* May 2020; 23(3S): S1-S127. PMID 32503359
37. Cohen SP, Bhaskar A, Bhatia A, et al. Consensus practice guidelines on interventions for lumbar facet joint pain from a multispecialty, international working group. *Reg Anesth Pain Med.* Jun 2020; 45(6): 424-467. PMID 32245841
38. Hurley RW, Adams MCB, Barad M, et al. Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group. *Reg Anesth Pain Med.* Jan 2022; 47(1): 3-59. PMID 34764220
39. Fornari M, Robertson SC, Pereira P, et al. Conservative Treatment and Percutaneous Pain Relief Techniques in Patients with Lumbar Spinal Stenosis: WFNS Spine Committee Recommendations. *World Neurosurg X.* Jul 2020; 7: 100079. PMID 32613192
40. National Institute for Health and Clinical Excellence (NICE). NICE guideline [NG59]: Low back pain and sciatica in over 16s: assessment and management. 2016
41. Evidence Based Clinical Guidelines for Multidisciplinary Spine Care: Diagnosis and Treatment of Low Back Pain. American Spine Society. Published 2020
42. Akgul MH, Akgun MY. Effect of radiofrequency denervation on pain severity among patients with cervical, thoracic or lumbar spinal pain: A clinical retrospective study. *Heliyon.* 2022;8(9):e10755. PMID: 36193536
43. Singh M, Karri J, Orhurhu V, Lachman L, Abd-Elsayed A. Radiofrequency Ablation for Thoracic and Abdominal Chronic Pain Syndromes. *Phys Med Rehabil Clin N Am.* 2021;32(4):647-666. PMID: 34593134

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>FACET JOINT DENERVATION</b>
<b>POLICY NUMBER</b>	<b>MP 5.049</b>

**POLICY HISTORY**

<b>MP 5.049</b>	<b>01/27/2022 Minor Review.</b> Removed “C3-4 and below” from policy statements, allowing just "cervical". Added criteria requiring other treatable causes of pain to be ruled out. Changed 50% reduction in pain to “sustained meaningful reduction (often defined as 50%)” in Policy Guideline section. Background and Rationale updated. References added. FEP language revised.
	<b>06/08/2023 Minor Review.</b> Added thoracic facet joints as medically necessary to policy statement for both first time and repeat treatments. Criteria now includes cervical, thoracic, lumbar, and lumbosacral facet joint. Therapeutic medial branch blocks changed from investigational to not medically necessary. Added codes 64490-64495. Background updated. References added.
	<b>05/28/2024 Minor Review.</b> Removed policy statement referring to therapeutic medial branch blocks. Background updated. References added.
	<b>04/24/2025 Minor Review.</b> First time treatments and subsequent treatments no longer separated. Added required medical record documentation to medically necessary criteria. Removed criteria for other treatable causes of pain. Added 6-month timeframe to prior successful radiofrequency denervation criteria. Moved repeat treatment criteria to Policy Guidelines. Rationale, Benefit Variation and Disclaimer updated. References added.
	<b>08/13/2025 Administrative Update.</b> Removed Benefit Variations Section and updated Disclaimer.

*Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.*